The estimated Net Worth of Pharma Llc Mazar Andrew Pau... is at least $2.23 Milion dollars as of 11 February 2021. Pharma Pau owns over 125,000 units of Monopar Therapeutics Inc stock worth over $400,001 and over the last 5 years Pharma sold MNPR stock worth over $1,830,000.
Pharma has made over 2 trades of the Monopar Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Pharma sold 125,000 units of MNPR stock worth $1,830,000 on 11 February 2021.
The largest trade Pharma's ever made was selling 125,000 units of Monopar Therapeutics Inc stock on 11 February 2021 worth over $1,830,000. On average, Pharma trades about 125,000 units every 211 days since 2019. As of 11 February 2021 Pharma still owns at least 166,667 units of Monopar Therapeutics Inc stock.
You can see the complete history of Pharma Pau stock trades at the bottom of the page.
Over the last 5 years, insiders at Monopar Therapeutics Inc have traded over $1,830,000 worth of Monopar Therapeutics Inc stock and bought 895,199 units worth $6,154,669 . The most active insiders traders include Michael J Brown, Diane Hendricks a Pharma Llc Mazar Andrew Pau.... On average, Monopar Therapeutics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $32,266. The most recent stock trade was executed by Andrew Cittadine on 30 June 2024, trading 8,952 units of MNPR stock currently worth $21,485.
monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
Monopar Therapeutics Inc executives and other stock owners filed with the SEC include: